OBJECTIVE: To investigate the clinical efficacy of montelukast plus budesonide nasal spray and desloratadine citrate disodium tablets on moderate and severe persistent allergic rhinitis. METHOD: Senenty patients with moderate and severe persistent allergic rhinitis were devided randomly study group (n = 35) and control group (n = 35). The study group were treated with montelukast sodium tablets combined with budesonide nasal spray and desloratadine citrate disodium tablets for 4 weeks, the control group received budesonide nasal spray and desloratadine citrate disodium tablets for 4 weeks. Comparing visual analogue scale (VAS) scores of nasal symptoms, rhino conjunctivitis quality of life questionnaire (RQLQ) scores and total effective rate in two groups at baseline and after treatment. RESULT: (1) VAS scores of nasal symptoms: the difference of total nasal symptoms VAS scores or single nasal symptom VAS scores from both groups at 2 weeks and 4 weeks after treatment were statistically significant (P < 0.05); (2) RQLQ scores: the difference of RQLQ scores of 2 group's at baseline and 4 weeks after treatment were statistically significant, the difference of RQLQ scores about nasal symptoms in two groups at 4 weeks after treatment were statistically significant (P < 0.05); (3) The total effective rate was 94.29% in study group but 80.00% in control group, the differences were statistically significant (P < 0.05). CONCLUSION Montelukast plus budesonide nasal spray and desloratadine citrate disodium tablets can work together better on relieving clinical syptoms quickly and promoting the life quality of patients with moderate and severe persistent allergic rhinitis.
Acetates ; administration & dosage ; therapeutic use ; Budesonide ; administration & dosage ; therapeutic use ; Humans ; Loratadine ; administration & dosage ; analogs & derivatives ; therapeutic use ; Nasal Sprays ; Quinolines ; administration & dosage ; therapeutic use ; Rhinitis, Allergic, Perennial ; drug therapy ; Surveys and Questionnaires

OBJECTIVE To observe clinical efficacy of azelastine hydrochloride nasal spray plus budesonide nasal spray on persistent allergic rhinitiss(AR). METHODS 120 patients with persistent AR were devided randomly into group A(n=40), group B(n=40) and group C(n=40). Group A were treated with azelastine hydrochloride nasal spray and budesonide nasal spray, group B received only azelastine hydrochloride nasal spray and group C received budesonide nasal spray only, the treatment process were 4 weeks. Clinical efficacy were compared among 3 groups 4 weeks later. RESULTS 1. VAS scores: VAS scores of nasal symptoms in group A were lower than those both in group B and in group C after 4 weeks, the difference were statistically significant(P<0.05); 2. RQLQ scores: RQLQ scores in 3 groups were all significantly improved after 4 weeks, the RQLQ scores of sleep, nonnose/eye symptoms, nasal symptoms and emotions in group A were improved more significantly than those in group B and in group C, the difference were statistically significant(P<0.05); 3. Clinical efficacy: the significant effective rate and the total effective rate were 50.00% and 93.33% in group A, but were 30.00% and 75.00% in group B and 27.50% and 77.50% in group C, the differences between group A and group B or group A and group C were statistically significant(P <0.05). CONCLUSION Azelastine hydrochloride nasal spray plus budesonide nasal spray can rapidly relieve nasal symptoms and improve the life quality of the patients with persistent AR.

Objective To evaluate the effect of embelin combined with paclitaxel on the inhibition of A 549 lung cancer cell proliferation and tumor growing in tumor bearing nude mice. Methods The anti-proliferation efficiency of embelin combined with paclitaxel were evaluated by MTT assay, and A 549 cell apoptosis were evaluated by lfow cytometry. A 549 cells were xenografted in mice to establish the animal model, which were used to evaluate the effect of anti-tumor. Results compared to saline group、embelin group and paclitaxel group, the (paclitaxel+embelin) group could inhibit the growth of A 549 cells effectively(P<0.05). The embelin combined with paclitaxel induced the apoptosis of A 549 cells more effective than paclitaxel alone. The (paclitaxel+embelin) group significantly inhibited the growth of tumor tissue. Conclusion the paclitaxel can inhibit the growth of A 549 cells, the embelin can induce the apoptosis of A 549 cells, and the combination of paclitaxel and embelin may be a potentially effective treatment for lung cancer.

Amyloid beta-peptides ( Aβ) is the key pathological feature of Alzheimer’s Disease (AD). Various factors contrib-ute to the accumulations of Aβ in the brains of patients. Among them, blood-brain barrier ( BBB) plays a crucial role in trans-porting Aβ between the brain and the bloodstream while this transfer function is mediated by the receptor of Aβon BBB. The abnormality of Aβ transport and related receptor expression can be detected in the brains of patients with AD, resulting in an un-usual increase in Aβlevels unusually increased . This review e-laborates the structure and function of BBB, the transport of Aβand the expression and transport mechanism of the related recep-tor, as well as summarizes the possible clearance strategy of Aβacross the BBB.

Objective To analyze the risk factors of clinically overt hemorrhagic cystitis(HC)(grade ≥Ⅱ) in 114 patients undergoing allogeneic hematopoietic stem cell transplantation(allo-HSCT) to predict the occurrence of HC.Methods We retrospectively analyzed 29 cases of clinically overt HC from a series of 114 patients subject to allo-HSCT from April 1997 to December 2004.The time of follow-up began from the day of initiating conditioning to day 180 post-transplant.The 11 clinical parameters were selected for univariate analysis using a Cox regression: age,sex,underlying disease,conditioning regimen,disease status at transplant,aGVHD,donor type,use of ATG,GVHD prophylaxis,platelet and neutrophil engraftment.Factors that were significant at the 0.1 level on univariate analysis were evaluated by multivariate analysis using a Cox regression.The cumulative incidence of grade ≥Ⅱ HC within the day 180 after transplantation was calculated by the method of Kaplan and Meier.Results Twenty-nine out of 114 patients(26 %) developed HC with grade Ⅱ in 12/29 cases(41.4 %),grade Ⅲ in 11/29 cases(37.9 %) and grade Ⅳ in 6/29 cases(20.7 %).The following factors were associated with an increased risk of HC by univariate analysis: male gender(RR=2.885,P=0.021),younger than 26 years(RR=3.265,P=0.002),gradeⅢ～Ⅳ aGVHD(RR=4.039,P=0.002),unrelated donor(RR=4.347,P=0.000),intense GVHD prophylaxis(RR=2.218,P=0.045),advanced disease(RR=2.668,P=0.009).These risk factors were entered into a multivariate model.Only male gender(RR=2.993,95 % CI 1.218-7.358;P=0.017) and unrelated donor(RR=4.478,95 % CI 2.049-9.786;P=0.000) were identified as being significantly associated with the occurrence of HC.Conclusion In multivariate analysis,patients were at increased risk of HC if they were male or had received grafts from unrelated donors.

Objective To study the effect of angiotensinⅡon the expression of monocyte chemoattractant protein-1 (MCP-1) in cultured human umbilical vein endothelial cells(hUVEC) , and the effect of peroxisome proliferator- activated receptors (PPARs)?and?on MCP-1. Methods MCP-1 protein level was detected by enzyme-linked immunosorbent assay (ELISA) method, and the mRNA expression level of MCP-1 was determined by RT-PCR. Results AngiotensinⅡdistinctly increased the expression of MCP-1 in a dose-dependent manner in cultured hUVECs, and valsartan inhibited the expression of MCP-1 remarkably. Both rosiglitazone (PPAR7 agonist) and fenofibrate (PPAR?agonist) concentration- dependently reduced the expression of MCP-1 in induced by AngⅡ10-6 mol/L. Conclusions AngiotensinⅡcan increase the expression of MCP-1 evidently in hUVECs, which is inhibited by valsartan. The activation of PPARa and PPAR?can decrease the expression of MCP-1 in hUVECs.

Objective To investigative the relationship of personality and coping style with subjective well-being in nurses.Methods 140 nurses were invited randomly to answer the questionnaires.123 questionnaires out of 140 were selected,with 17 papers excluded because of un-complete answer.Personality,coping style and subjective well-being were respectively estimated with Eysenck Personality Questionnaire(EPQ),Simplified Coping Style Questionnaire(SCSQ) and General Well-Being Scale(GWB).The resuits were compared with the national norm.Correlation analysis was performed in term of the correlation of personality and coping style with subjective well-being.Results Subjective well-being of nurses was associated with personality and coping style.Conclusions Personality and coping style can predict subjective well-being.The research can provide theoretical basis for psychological care to the nurse group.

Objective To set up the standard for the quality control of Chongcaojing Oral Liquid.Methods Radix Astragal-i,Radix Ginseng,Radix Angelicae Si nensis,Radix Rehmanniae were ident ified quantitatively by thin -layer chromatog-raphy(TLC)and astragalosideⅣcontent in Radix Astragali was determined by TLC scanning quantitiatvely.Results The TLC spots were highly specific,clea r and concentrated without the interference of negative controls.Linearity was ob-tained in the range of 1.03～6.15?g(r =0.9994).The average recovery was 99.2%with RSD =1.8%.Conclu-sion This method is sensitive,simple,sp ecific and accurate for the quality c ontrol of Chongcaojing Oral Liquid.

Objective To establish a method for the content determination of berberine hydrochloride in Xiaoyou Capsules.Method A PR-HPLC method was adopted with a SHIMADZU RP-ODS C18 column as stationary phase and 0.05 mol/L KH2PO4(adjust pH to 3 with H3PO4)-Acetonitrile(70:30)as mobile phase.The detector wavelength was at 265 nm,column temperature was at 40 ℃and the flow rate was 1.0 mL/min.Results Berberine hydrochloride in Xiaoyou capsules showed a good linearity in the range of 0.010 73～0.214 6 ?g.The average recovery was 99.87 %,RSD was 1.43 %.Conclusion The method is simple,reliable,with a good separation,so it can be used for the quality control of Xiaoyou Capsules.

Objective To investigate relationship between the expressions of TGF-β1 mRNA, Smad7 mRNA and ki-67 mRNA and the clinicopathologic characteristics in gastric carcinoma. Methods 60 cases with gastric carcinoma tissue and 20 cases with normal gastric tissue, which were surgically removed and certified by pathology, were collected. The expressions of TGF-β1 mRNA, Smad7 mRNA and ki-67 mRNA were detected by RT-PCR in normal and carcinomatous gastric tissue. Results The expressions of TGF-β1 mRNA, Smad7 mRNA and ki-67 mRNA in normal gastric tissue were lower than those in carcinomatous gastric tissue (P < 0.05). The expressions of TGF-β1 mRNA, Smad7 mRNA and ki-67 mRNA in gastric carcinoma which were well differentiated and moderately differentiated were significantly lower than those in poorly differentiated gastric carcinoma (P<0.05). The expressions of TGF-β1 mRNA, Smad7 mRNA and ki-67 mRNA in gastric carcinoma without lymph node metastasis were lower than those in gastric carcinoma with lymph node metastasis. The expressions of TGF-β1 mRNA, Smad7 mRNA and ki-67 mRNA in Ⅰ+Ⅱ stage were lower those in Ⅲ+Ⅳ stage (P < 0.05). Linear correlation showed there were positive correlations among TGF-β1 mRNA, Smad7 mRNA and ki-67 mRNA in gastric carcinoma. Conclusions The canonical TGF-β1 Smad7 and Ki-67 mRNA play a role in the carcinogenesis, development, differentiation of gastric carcinoma.